



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on 2/4/04

Kathy Mueller
Name of Person Mailing Document
Kathy Mueller
Signature of Person Mailing Document

P&G Case 7294C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :
Donald C. Roe et al. : Confirmation No.
Serial No. 10/757,813 : Group Art Unit
Filed January 15, 2004 : Examiner

For Article Having Improved Fecal Storage Structure

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☒ 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☐ **37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. ☐ **37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. ☐ **37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. ☐ **Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case)**. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

**ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:**

☒ (2) (For use with applications filed after June 30, 2003.) In accordance with 37 C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign patent documents and non-patent literature.

OR

☒ (3) All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. 7294, U.S. Patent Application Serial No. 09/172,405, filed October 14, 1998. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

OR

☐ (4) Copies of all said documents, except Cite Numbers _____, were submitted and considered in parent application U.S. Patent Application Serial No. _____, filed _____. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.


☐ (5) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

☐ (6) Applicants also respectfully request the Examiner to consider and make of record the co-pending applications listed on the attached page.

☐ Additional information is attached.

Respectfully submitted,


By


Jay A. Krebs
Attorney for Applicant(s)
Registration No. 41,914
(513) 626-4856

Date: 2-4-04
Customer No. 27752

(IDS.doc) (Last Revised 10/10/03)

Please type a plus sign (+) inside this box → [+]



PTO/SB08A (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

COMPLETE IF KNOWN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 5

Application Number	10/757,813
Confirmation Number	
Filing Date	January 15, 2004
First Named Inventor	Donald C. Roe et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	7294C

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		2,896,618	7/28/59	Schaefer	
		3,284,273	11/8/66	Prentice	
		3,371,667	3/5/68	Morse	
		3,489,148	1/13/70	Duncan et al.	
		3,491,759	1/27/70	Samuel	
		3,532,097	10/6/70	Jones, Sr.	
		3,585,998	6/22/71	Hayford	
		3,593,717	7/20/71	Jones, Sr.	
		3,759,262	9/18/73	Jones, Sr.	
		3,848,594	11/19/74	Buell	
		3,860,003	1/14/75	Buell	
		3,875,942	4/8/75	Roberts et al.	
		3,890,973	6/24/75	Davis et al.	
		3,896,807	7/29/75	Buchalter	
		3,911,173	10/7/75	Sprague, Jr.	
		3,929,135	12/30/75	Thompson	
		3,945,386	3/23/76	Anczurowski et al.	
		3,964,486	6/22/76	Blaney	
		3,967,623	7/6/76	Butterworth et al.	
		4,027,672	6/7/77	Karami	
		4,047,531	9/13/77	Karami	
		4,055,180	10/25/77	Karami	
		4,173,042	11/6/79	Krzewinski-Morris	
		4,321,924	3/30/82	Ahr	
		4,324,246	4/13/82	Mullane et al.	
		4,324,247	4/13/82	Aziz	
		4,342,314	8/3/82	Radel et al.	
		4,360,021	11/23/82	Stima	
		4,381,781	5/3/83	Sciaraffa et al.	
		4,381,782	5/3/83	Mazurak et al.	
		4,385,632	5/31/83	Odelhög	
		4,392,861	7/12/83	Butterworth et al.	
		4,397,644	8/9/83	Matthews et al.	
		4,401,712	8/30/83	Morrison	
		4,463,045	7/31/84	Ahr et al.	
		4,501,586	2/26/85	Holtman	
		4,515,595	5/7/85	Kievit et al.	
		4,556,560	12/3/85	Buckingham	
		4,573,986	3/4/86	Minetola et al.	
		4,609,518	9/2/86	Curro et al.	
		4,610,678	9/9/86	Weisman et al.	
		4,613,447	9/23/86	Hara et al.	
		4,622,036	11/11/86	Goodrum	
		4,623,339	11/18/86	Ciraldo et al.	
		4,629,643	12/16/86	Curro et al.	
		4,643,727	2/17/87	Rosenbaum	

	4,657,537	4/14/87	Zimmerer	
	4,662,875	5/5/87	Hirotsu et al.	
	4,662,877	5/5/87	Williams	
	4,673,402	6/16/87	Weisman et al.	
	4,676,785	6/30/87	Battista	
	4,678,464	7/7/87	Holtman	
	4,685,909	8/11/87	Berg et al.	
	4,695,278	9/22/87	Lawson	
	4,699,823	10/13/87	Kellenberger, et al.	
	4,704,112	11/3/87	Suzuki et al.	
	4,710,189	12/1/87	Lash	
	4,723,953	2/9/88	Rosenbaum et al.	
	4,785,996	11/22/88	Ziecker et al.	
	4,790,836	12/13/88	Brecher	
	4,795,454	1/3/89	Dragoo	
	4,798,603	1/17/89	Meyer et al.	
	4,804,378	2/14/89	Shiba et al.	
	4,808,178	2/28/89	Aziz et al.	
	4,816,025	3/28/89	Foreman	
	4,834,735	5/30/89	Aleman et al.	
	4,842,593	6/27/89	Jordan et al.	
	4,842,666	6/27/89	Werenicz	
	4,846,815	7/11/89	Scripps	
	4,857,067	8/15/89	Wood et al.	
	4,885,204	12/5/89	Bither et al.	
	4,888,231	12/19/89	Angstadt	
	4,892,536	1/9/90	DesMarais et al.	
	4,894,060	1/16/90	Nestegard	
	4,908,026	3/13/90	Sukiennik et al.	
	4,909,803	3/20/90	Aziz et al.	
	4,938,753	7/3/90	Van Gompel et al.	
	4,946,527	8/7/90	Battrell	
	4,963,140	10/16/90	Robertson et al.	
	4,968,312	11/6/90	Khan	
	4,988,344	1/29/91	Reising et al.	
	4,988,345	1/29/91	Reising	
	4,990,147	2/5/91	Freeland	
	5,006,394	4/9/91	Baird	
	5,026,364	6/25/91	Robertson	
	5,037,409	8/6/91	Chen et al.	
	5,037,416	8/6/91	Allen et al.	
	5,062,840	11/5/91	Holt et al.	
	5,062,840	11/5/91	Holt et al.	
	5,071,681	12/10/91	Manning et al.	
	5,098,764	3/24/92	Drelich et al.	
	5,124,197	6/23/92	Bernardin et al.	
	5,134,007	7/28/92	Reising et al.	
	5,135,521	8/4/92	Luceri et al.	
	5,137,537	8/11/92	Herron et al.	
	5,143,779	9/1/92	Newkirk et al.	
	5,147,343	9/15/92	Kellenberger	
	5,147,345	9/15/92	Young et al.	
	5,149,335	9/22/92	Kellenberger et al.	
	5,151,092	9/29/92	Buell et al.	
	5,171,236	12/15/92	Dreier et al.	
	5,171,238	12/15/92	Kajander	
	5,176,672	1/5/93	Bruemmer et al.	
	5,192,277	3/9/93	Chung et al.	
	5,192,606	3/9/93	Proxmire et al.	
	5,204,158	4/20/93	Phillips et al	
	5,207,663	5/4/93	McQueen	
	5,221,274	6/22/93	Buell et al.	
	5,244,711	9/14/93	Drelich et al.	
	5,260,345	11/9/93	DesMarais et al.	
	5,269,775	12/14/93	Freeland et al.	
	5,281,208	1/25/94	Thompson et al.	

		5,304,159	4/19/94	Tanji et al.	
		5,304,160	4/19/94	Igaue et al.	
		5,306,266	4/26/94	Freeland	
		5,330,459	7/19/94	Lavon et al.	
		5,342,338	8/30/94	Roe	
		5,342,342	8/30/94	Kitaoka	
		5,344,516	9/6/94	Tanji et al.	
		5,352,217	10/4/94	Curro	
		5,356,405	10/18/94	Thompson et al.	
		5,387,207	2/7/95	Dyer et al.	
		5,387,209	2/7/95	Yamamoto et al.	
		5,397,318	3/14/95	Dreier	
		5,429,632	7/4/95	Tanji et al.	
		5,439,458	8/8/95	Noel et al.	
		5,439,459	8/8/95	Tanji et al.	
		5,462,541	10/31/95	Bruemmer et al.	
		5,468,236	11/21/95	Everhart et al.	
		5,514,121	5/7/96	Roe et al.	
		5,518,801	5/21/96	Chappell et al.	
		5,520,674	5/28/96	Lavon et al.	
		5,525,346	6/11/96	Hartung et al.	
		5,540,671	7/30/96	Dreier	
		5,545,155	8/13/96	Hseih et al.	
		5,554,142	9/10/96	Dreier et al.	
		5,569,234	10/29/96	Buell et al.	
		5,571,096	11/5/96	Dobrin et al.	
		5,579,722	12/3/96	Yamamoto et al.	
		5,580,411	12/3/96	Nease et al.	
		5,586,978	12/24/96	Bayne	
		5,603,707	2/18/97	Trombetta et al.	
		5,607,760	3/4/97	Roe	
		5,609,587	3/11/97	Roe	
		5,628,097	5/13/97	Benson et al.	
		5,635,191	6/3/97	Roe et al.	
		5,643,588	7/1/97	Roe et al.	
		5,650,222	7/22/97	DesMarais	
		5,653,703	8/5/97	Roe et al.	
		5,669,897	9/23/97	Lavon et al.	
		5,674,213	10/7/97	Sauer	
		5,676,661	10/14/97	Faulks et al.	
		5,776,122	7/7/98	Faulks et al.	
		5,779,690	7/14/98	Gustafsson et al.	
		5,810,798	9/22/98	Finch et al.	
		5,824,172	10/20/98	Kielpikowski	
		5,830,203	11/3/98	Suzuki et al.	
		5,865,823	2/2/99	Curro	
		5,925,026	7/20/99	Arteman et al.	
		5,938,650	8/17/99	Baer et al.	
		5,941,863	8/24/99	Guidotti et al.	
		5,976,665	11/2/99	Hansson	
		6,004,306	12/21/99	Robles et al.	
		SIR #H1670	7/1/97	Aziz et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
		CA	2,049,398		2/18/92	Kimberly-Clark Corporation		
		DE	3 301 555 A1		8/2/84	Vereinigte Papierwerke Schickedanz & Co.		
		DE	4,136,540		5/14/92	American Israeli Paper Mills Ltd.		
		EP	0 059 498 A1		9/8/92	The Procter & Gamble Co.		
		EP	0 160 569 A2		11/6/85	Personal Products Company		
		EP	0 160 572 A2		11/6/85	Personal Products Company		

	EP 0 193 309 A1	9/3/86	Nishino, Tetsuya		
	EP 0 215 417 A1	3/25/87	Kimberly-Clark Corporation		
	EP 0 355 740 A2	2/28/90	Kimberly-Clark Corporation		
	EP 0 359 501 B1	12/7/94	Johnson & Johnson Inc.		
	EP 0 418 493 A1	3/27/91	Fiberweb North America, Inc.		
	EP 0 470 392 A1	2/12/92	Kimberly-Clark Corporation		
	EP 0 495 212 A1	7/22/92	Nitto Denko Corporation		
	EP 0 545 423 A1	6/9/93	Uni-Charm Corporation		
	EP 0 581 044	2/2/94	Uni-Charm Corporation		
	EP 0 626 161	11/30/94	Japan Absorbent Technology Institute		
	EP 0 745 367	12/4/96	Uni-Charm Corporation		
	EP 0 758 543	2/19/97	Uni-Charm Corporation		
	EP 0 847 738	6/17/98	The Procter & Gamble Co.		
	EP 0 933 074	8/4/99	Uni-Charm Corporation		
	ES 2,022,026	11/16/91	Gutierrez Martin Francisca		
	FR 2,504,799	11/5/82	Verdoy Fursy		
	FR 2,561,078	9/20/85	Lefebvre Serge		
	GB 2 255 720 A	11/18/92	Kao Corporation		
	GB 2,103,933A	3/2/83	Smith and Nephew Associated Companies Ltd.		
	GB 2,268,073	1/5/94	Uni-Charm Corporation		
	JP 2,518,012	11/20/96	None		
	JP 2,547,103	5/16/97	Sharp KK		
	JP 2,559,049	9/12/97	Nippon Telegraph & Telephone		
	JP 2,559,752	9/19/97	Canon KK		
	JP 2,565,491	10/3/96	Uni-Charm Corporation		
	JP 2,565,492	10/3/96	Uni-Charm Corporation		
	JP 2,565,493	10/3/96	Uni-Charm Corporation		
	JP2-31756	2/1/90	None		
	JP3-202,057	9/3/91	Kao Corporation		
	JP 4-152945	10/16/90	Uni-Charm Corporation		
	JP 4-221556	8/12/92	Kao Corporation		
	JP5-49659	8/21/91	None		
	JP5-86320	11/22/93	None		
	JP6-038,818	5/25/94	None		
	JP6-102070	12/14/94	None		
	JP6-17726	3/8/94	None		
	JP6-31723	4/26/94	None		
	JP6-34618	5/10/94	None		
	JP6-74132	10/21/94	None		
	JP7-7620	2/3/95	NEC Corporation		
	JP8-117261	5/14/96	Beppu Yoshio		
	JP8-191857	7/30/96	Uni-Charm Corporation		
	JP9-141091	6/3/97	Showa Denko KK		
	JP9-238979	9/16/97	Oji Paper Co. Ltd.		
	JP9-276333	10/28/97	Oji Paper Co. Ltd.		
	JP9-51911	2/25/97	None		
	JP10-14978	1/20/98	Nippon Steel Corp.		
	JP10-14979	1/20/98	Nippon Steel Corp.		
	JP10-165436	6/23/98	Kao Corporation		
	JP10-192339	7/28/98	Uni-Charm Corporation		
	JP10-234760	9/8/98	Nishimura Koichi		
	JP10-234775	9/8/98	Uni-Charm Corporation		
	WO 93/09741	5/27/93	The Procter & Gamble Co.		
	WO 93/09744	5/27/93	The Procter & Gamble Co.		
	WO 93/25172	12/23/93	The Procter & Gamble Co.		
	WO 94/14395	7/7/94	The Procter & Gamble Co.		
	WO 95/16417	6/22/95	Indiana Cash Drawer Co., Inc.		
	WO 95/16418	6/22/95	Mölnlycke AB		
	WO 95/16422	6/22/95	Kimberly-Clark Corporation		
	WO 95/16746	6/22/95	E.I. Du Pont De Nemours And Company		

	WO 95/24173	9/14/95	The Procter & Gamble Co.		
	WO 95/25493	9/28/95	Mölnlycke AB		
	WO 96/09026	3/28/96	The Procter & Gamble Co.		
	WO 96/19167	6/27/96	Kimberly-Clark Corporation		
	WO 96/23466	8/8/96	Mölnlycke AB		
	WO 96/23467	8/8/96	Mölnlycke AB		
	WO 96/40029	12/19/96	Kimberly-Clark Corporation		
	WO 97/01316	1/16/97	Bautista Moreno		
	WO 97/02846	1/30/97	SCA Mölnlycke AB		
	WO 97/14385	4/24/97	Marlene Sandberg AB		
	WO 97/14388	4/24/97	Eastman Chemical Co.		
	WO 97/16144	5/9/97	Kimberly-Clark Worldwide, Inc.		
	WO 97/21409	6/19/97	Kimberly-Clark Worldwide, Inc.		
	WO 97/22319	6/26/97	Kimberly-Clark Worldwide, Inc.		
	WO 97/49366	12/31/97	Kimberly-Clark Worldwide, Inc.		
	WO 98/08476	3/5/98	Kimberly-Clark Worldwide, Inc.		
	WO 98/16179	4/23/98	The Procter & Gamble Co.		
	WO 98/16180	4/23/98	Kimberly-Clark Worldwide, Inc.		
	WO 98/17219	4/30/98	Kimberly-Clark Worldwide, Inc.		
	WO 98/27907	7/2/98	Kimberly-Clark Worldwide, Inc.		
	WO 98/37839	9/3/98	SCA Mölnlycke AB		
	WO 98/37839	9/3/98	SCA Mölnlycke AB		
	WO 98/37844	9/3/98	SCA Mölnlycke AB		
	WO 99/30661	6/24/99	SCA Hygiene Products AB		
EXAMINER			DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.